Guardant Health (NASDAQ:GH) Now Covered by Barclays

Barclays started coverage on shares of Guardant Health (NASDAQ:GH) in a report issued on Thursday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $60.00 target price on the stock.

Several other research firms have also commented on GH. Leerink Partners cut their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein lowered their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. The Goldman Sachs Group raised their price objective on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Guardant Health in a research report on Wednesday. Sixteen analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has a consensus rating of “Buy” and a consensus price target of $41.81.

Guardant Health Stock Down 2.9 %

Shares of NASDAQ GH opened at $47.21 on Thursday. The stock has a market capitalization of $5.83 billion, a PE ratio of -11.13 and a beta of 1.28. The firm has a fifty day moving average of $35.26 and a 200-day moving average of $29.54. Guardant Health has a 52-week low of $15.81 and a 52-week high of $49.86.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analysts’ expectations of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the firm posted ($0.73) EPS. Equities research analysts expect that Guardant Health will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the sale, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,548 shares of company stock worth $179,782. Insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of hedge funds have recently bought and sold shares of GH. R Squared Ltd purchased a new stake in Guardant Health in the 4th quarter worth about $26,000. JNBA Financial Advisors acquired a new position in shares of Guardant Health in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Guardant Health in the third quarter worth approximately $34,000. Quarry LP acquired a new stake in shares of Guardant Health during the second quarter worth approximately $44,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health during the second quarter valued at approximately $71,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.